Cellectar Biosciences

I-131-CLR1404 Injection is a small-molecule radiopharmaceutical developed by Cellectar Biosciences for the treatment of glioma. The program, internally designated DCL-13-001, reached Phase 2 clinical development but was terminated as of February 2014. The drug is an iodine-131-based injection formulation, representing a radionuclide therapeutic approach to central nervous system malignancy. Cellectar's strategy centered on evaluating the agent in glioma patients through controlled clinical trials. The most recent disclosed milestone occurred on 25 February 2014, marking the end of active development for this indication. The program's termination reflects either strategic reprioritization, clinical or commercial challenges, or resource allocation decisions by the sponsor. No mechanism of action, specific molecular target, or detailed efficacy/safety data have been disclosed in available records. The competitive landscape for glioma includes multiple Phase 2 and Phase 3 agents targeting various pathways, including kinase inhibitors, radionuclide therapies, and chemotherapy combinations.

Glioma represents a significant unmet medical need, particularly high-grade glioblastoma, which carries poor prognosis despite standard-of-care temozolomide and radiation therapy. Novel therapeutic approaches, including targeted small molecules and radionuclide-based therapies, are actively pursued to improve survival and quality of life. Radiopharmaceutical approaches offer potential advantages through targeted delivery and localized cytotoxicity, particularly relevant for CNS tumors where blood-brain barrier penetration is a critical challenge. The termination of I-131-CLR1404 suggests that despite theoretical promise, the program did not advance to later-stage development, indicating either insufficient efficacy signals, safety concerns, or competitive disadvantage relative to emerging alternatives. The glioma market remains highly competitive, with multiple Phase 2 and Phase 3 programs evaluating kinase inhibitors (paxalisib, BGJ398), radionuclide therapies (177Lu-DOTATOC), and combination chemotherapy regimens. Understanding why this program was discontinued provides insight into clinical development challenges in CNS oncology and the high bar for advancement in this indication. The patient population affected by glioma is substantial but represents a specialized market segment requiring differentiated efficacy and safety profiles to justify development investment.

Drug Class: Radiopharmaceutical (radionuclide therapeutic)

Modality: Small molecule

Active Component: Iodine-131 (I-131)

Route of Administration: Injection (intravenous presumed, not explicitly stated)

Mechanism of Action: Not disclosed

Molecular Target: Not disclosed

Related Therapies: Other radionuclide-based approaches include 177Lu-DOTATOC (somatostatin receptor-targeted radionuclide therapy). Competitive small-molecule kinase inhibitors in glioma development include paxalisib (PI3K inhibitor), BGJ398 (FGFR inhibitor), and tovorafenib (BRAF inhibitor). Standard-of-care chemotherapy includes temozolomide and carboplatin-based combinations.

Patent Status: Not disclosed

First Approval: Not applicable; program terminated in Phase 2

FDA Status: Not yet disclosed. Program terminated in Phase 2; no IND status, clinical hold, or regulatory correspondence disclosed.

EMA Status: Not yet disclosed.

PMDA (Japan) Status: Not yet disclosed.

NMPA (China) Status: Clinical trials status indicated for the drug product across multiple NCT identifiers (NCT03062774, NCT04493840, NCT05154630, NCT05164458, NCT05171790, NCT05405621, NCT05489276, NCT05584800, NCT05619926, NCT05735496), though these may represent other Cellectar programs or unrelated trials. No approval history or regulatory milestones are disclosed for I-131-CLR1404 Injection specifically.

Regulatory Pathway: Not yet disclosed. Radionuclide therapeutics typically require specialized regulatory review including dosimetry, biodistribution, and radiation safety assessments.

Strategic Implications: The termination of I-131-CLR1404 in Phase 2 indicates that Cellectar Biosciences either encountered insufficient efficacy signals, unacceptable toxicity, or competitive disadvantage in glioma. The lack of disclosed mechanism of action and molecular target suggests the program may have lacked clear differentiation from existing therapies or emerging competitors. Cellectar's subsequent strategic focus (if any) on alternative indications or mechanisms is not disclosed.

Competitive Implications: The advancement of multiple Phase 3 kinase inhibitors and combination chemotherapy regimens in glioma suggests that targeted molecular approaches and optimized chemotherapy combinations may offer greater clinical benefit than the I-131-CLR1404 approach. The success of receptor-targeted radionuclide therapies (e.g., 177Lu-DOTATOC) in other indications did not translate to glioma advancement for this program, potentially reflecting inadequate target expression, blood-brain barrier penetration challenges, or insufficient therapeutic window.

Future Catalysts: No future milestones are expected for this terminated program. Publication of Phase 2 safety and efficacy data, if conducted, would provide insight into reasons for termination.

Expected Milestones: None; program is terminated.